当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program.
Cancer Discovery ( IF 28.2 ) Pub Date : 2022-04-01 , DOI: 10.1158/2159-8290.cd-21-1064
Kyong Hwa Park 1, 2 , Jung Yoon Choi 1, 2 , Ah-Reum Lim 1, 2 , Ju Won Kim 1, 2 , Yoon Ji Choi 1, 2 , Soohyeon Lee 1, 2 , Jae Sook Sung 2 , Hee-Joon Chung 2 , Byunghyun Jang 3 , Dayoung Yoon 3, 4 , Sukwon Kim 3 , Jason K Sa 3 , Yeul Hong Kim 1, 2
Affiliation  

The fundamental principle of precision oncology is centralized on the identification of therapeutically exploitable targets that provides individual patients with cancer an opportunity to make informed decisions on a personalized level. To facilitate and adopt such concepts within clinical practice, we have initiated a nationwide, multi-institutional precision oncology screening program to examine and enroll patients into the most appropriate clinical trial based on their tumor's unique molecular properties. To determine the prevalence of essential major driver mutations and to explore their dynamic associations at both molecular and pathway levels, we present a comprehensive overview on the genomic properties of East Asian patients with cancer. We further delineate the extent of genomic diversity as well as clinical actionability in patients from Western and Eastern cultures at the pan-cancer and single-tumor entity levels. To support fellow oncology communities in future investigations involving large-scale analysis, all data have been made accessible to the public (https://kmportal.or.kr). SIGNIFICANCE We present a comprehensive overview of molecular properties of East Asian pan-cancer patients and demonstrate significant diversity in terms of genomic characteristics as well as clinical utility compared with patients with European ancestry. The results of this study will lay the groundwork for designing personalized treatments in the clinical setting. See related commentary by Moyers and Subbiah, p. 886. This article is highlighted in the In This Issue feature, p. 873.

中文翻译:

来自前瞻性临床测序的韩国晚期泛癌患者的基因组景观和临床效用:K-MASTER 计划。

精准肿瘤学的基本原则集中在治疗可利用靶点的识别上,这些靶点为癌症患者个体提供了在个性化水平上做出明智决策的机会。为了在临床实践中促进和采用这些概念,我们启动了一项全国性、多机构的精准肿瘤学筛查计划,以根据患者肿瘤的独特分子特性检查患者并将其纳入最合适的临床试验。为了确定重要的主要驱动突变的普遍性并探索它们在分子和通路水平上的动态关联,我们对东亚癌症患者的基因组特性进行了全面概述。我们进一步描述了基因组多样性的程度以及来自西方和东方文化的患者在泛癌和单肿瘤实体水平上的临床可操作性。为了在未来涉及大规模分析的调查中支持其他肿瘤学社区,所有数据都已向公众开放 (https://kmportal.or.kr)。意义 我们全面概述了东亚泛癌患者的分子特性,并展示了与欧洲血统患者相比在基因组特征和临床效用方面的显着差异。这项研究的结果将为在临床环境中设计个性化治疗奠定基础。参见 Moyers 和 Subbiah 的相关评论,p. 886. 这篇文章在本期专题中突出显示,p。873.
更新日期:2021-12-03
down
wechat
bug